Klick Health's recent acquisition of Oxford PharmaGenesis reflects that shift. “Clearly for a lot of reasons that have been ...

Day One Strategy’s second annual AI in Pharma State of Play report – Are Insights leaders seeing real commercial value from AI adoption yet? – addresses the challenges Pharma Insights teams are facing ...

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia – a digital ...

When pharmaphorum last spoke with MRM Health founder and CEO Sam Possemiers at JP Morgan, he told us about his company’s microbiome-based therapy for ulcerative colitis. At LSX USA in Boston last ...

As antibody-drug conjugates (ADCs) continue to establish themselves as a cornerstone of modern oncology, breakthrough ...

AstraZeneca's pivot towards the US market has continued with the opening of a new R&D centre in the biotech hotspot of ...

The UK government has said it will accept all 44 recommendations made in a recently published report on using AI tools in the NHS, including continual monitoring after deployment. This morning, the ...